|
|
Please type responses here: |
|
First Name:
|
|
|
Last Name:
|
|
|
Email Address:
|
|
|
Retype Email Address:
|
|
|
Title:
|
|
|
Institution:
|
|
|
Phone Number:
|
|
|
City:
|
|
|
State/Province:
|
|
|
Postal/Zip Code:
|
|
|
Country:
|
|
|
What topics would you like to see covered in future POC Group Webinars?
|
|
|
Overall, how would you rate your satisfaction with this Point of Care Web Meeting?
|
Extremely satisfied
Very satisfied
Somewhat satisfied
Dissatisfied
|
|
Your feedback helps your webinar producers and sponsors improve the overall quality of their products and services.
|
|
What device types are you considering adding to your middleware system in 2023? Choose all that apply:
|
Blood Gas
Coagulation
Urinalysis
Hemoglobin
Flu
Strep
PT/INR
SARS-CoV
Manual Tests
Other
|
|
If you chose ‘other’ in the question above, please list the device type(s) are you considering adding to your middleware system in 2023:
|
|
|
What current data management system(s) are you using? Choose all that apply:
|
Abbott PrecisionWeb™
GEMweb® Plus
Orchard® Trellis™
Radiometer AQURE
Radiometer Radiance
RALS™ Connectivity System
Roche cobas® IT 1000 / cobas® infinity POC
SIEMENS POCcelerator™
SIEMENS RapidComm®
SIEMENS UniPOC™
Telcor QML®
None
Other
|
|
If you chose ‘other’ in the question above, please list your current data management system(s):
|
|
|
Do you currently use Cepheid tests?
|
Yes
No
|
|
Are you looking to add any new CLIA waived molecular tests this year?
|
Yes
No
|
|
Would you like to be contacted to learn more about Cepheid's POC solutions?
|
Yes
No
|
|
How familiar are you with the LumiraDx Platform?
|
0
1
2
3
4
5
6
7
8
9
10
|
|
Consider the following point-of-care viral testing options for upper respiratory infections. For testing during the respiratory season, which assay configuration would be most preferred by your institution:
|
Single test: multiplex simultaneous test for SARS-CoV-2 + Flu A/B + RSV
Two tests: a multiplex tests for SARS-CoV-2 + Flu A/B, and a separate RSV test
Three separate tests: (1) SARS-CoV-2 (2) Flu A/B, and (3) RSV test
Other
N/A
|
|
If you chose 'other' in the question above, please specify the assay configuration your institution would prefer:
|
|
|
What type of point of care tests do you currently utilize? Please check all that apply:
|
Diabetes monitoring (HbA1c)
Lipid Panel
COVID-19
Flu
Strep
Drugs of Abuse
Other
I do not do point of care testing
|
|
Would you like to know more about Abbott’s HbA1c and cholesterol point of care testing offerings?
|
Yes – Both HbA1c and Cholesterol Testing
Yes- HbA1c only
Yes- Cholesterol only
No
Not Sure
|
|
What is the preferred method for you to receive POC product-specific updates on products used in your facility?
|
Email to your work email address
Email to a general POC department mailbox
Physical mailer to POC department
Other
|
|
If you chose ‘other’ in the question above, please specify:
|
|
|
If your facility has a general POC department mailbox where you would want product updates to be sent, please provide the address below:
|
|
|
Would you like to receive EITHER ASCLS PACE credit for this session, program number 174-002-23, OR Florida CE credit? (If no, you do not need to complete the following questions.)
|
Yes
No
|
|
Which continuing education credit would you like to receive for this session?
|
PACE
Florida CE Credit
I would not like CE credit for this session
|
|
If you are planning to submit this session for Florida CE Credit, please provide your Florida license number:
|
|
|
To receive ASCLS PACE credit (PACE Program number 174-002-23, California Agency #0001) OR FloridaCE credit for "Pediatric Care at the Point of Care" presented on February 14, 2023, you will be required to complete the following program evaluation.
|
|
If the following is true, please answer "Yes": I have attended the full instructional time for this program. I understand that completion of the program is necessary to receive the contact hours awarded for the program.
|
Yes
No
|
|
SPEAKER RATING
|
|
To what extent was the speaker knowledgeable, organized and effective during the presentation? (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
Not applicable
|
|
To what extent did the speaker clarify and focus on the stated objectives? (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
Not applicable
|
|
To what extent were the speaker's teaching methods & aids appropriate & effective? (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
Not applicable
|
|
OBJECTIVES RATING:
To what extent was each objective achieved?
|
|
Identify the causes of intraoperative cardiac surgical bleeding, and explain how TEG allows surgical teams to rapidly target bleeding causes and accurately plan effective blood component therapy. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Explore how TEG platelet mapping and heparin effect analysis help guide long term anticoagulation for pediatric patients on mechanical circulatory support. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Describe how an interfaced POC middleware can simplify the training and competency process, save time, and reduce errors. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Describe the value of POCT in the provision of ECMO life support. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Describe limitations of NOT using POCT while providing ECMO life support. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
PROGRAM CONTENT RATING
|
|
To what extent did the program content relate to the program's objectives? (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Rate the contribution of this session to your overall knowledge of this subject. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent)
|
1
2
3
4
|
|
Rate your overall degree of satisfaction with this session. (1 is Low, 2 is Poor, 3 is High, 4 is Excellent).
|
1
2
3
4
|
|
Comments:
|
|
|
Thank you for attending this PACE approved program and completing this evaluation. Questions? Call Whitehat Communications at 434 202 8365.
|
|
|
_w-o_webinars.jpg)